Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Shanghai Stock Exchange 688266.SS

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 41.83

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Price to Sales Ratio (P/S) is 41.83 on January 14, 2025, a 23.55% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 50.97 on October 08, 2024, which is 21.86% above the current Price to Sales Ratio (P/S).
Suzhou Zelgen Biopharmaceuticals Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 23.50 on February 05, 2024, which is -43.80% below the current Price to Sales Ratio (P/S).
Suzhou Zelgen Biopharmaceuticals Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 37.80.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 688266.SS

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

CEO	Mr. Zelin Sheng
IPO Date	Jan. 23, 2020
Location	China
Headquarters	No. 209, Chenfeng Road
Employees	867
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.

Key trends

Past 5 years